Acquired hemophilia A (AHA) is a rare disease resulting from autoantibodies (inhibitors) against endogenous factor VIII (FVIII) that leads to bleeding, which is often spontaneous and severe. AHA tends to occur in elderly patients with comorbidities and is associated with high mortality risk from underlying comorbidities, bleeding, or treatment complications. Treatment, which consists of hemostatic management and eradication of the inhibitors, can be challenging to manage. 
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What is the epidemiology of AHA?
AHA is predominantly a disease of the elderly (median age 64-78 years), [1] [2] [3] [4] [5] [6] [7] [8] but can be associated with pregnancy [1] [2] [3] [4] [5] [6] [7] 9 and autoimmune disease in younger cohorts. Most cases are idiopathic (43.6%-51.9%), [1] [2] [3] [4] [5] [6] [7] but AHA is also associated with malignancy (6.4%-18.4%), autoimmune disorders (9.4%-17.0%, most commonly rheumatoid arthritis), [1] [2] [3] [4] [5] [6] [7] [8] 10 infections, dermatologic conditions, and certain medications (eg, interferon alpha). 5 Pediatric cases are rare; a review reported 42 cases in children, including six related to transplacental crossing of maternal antibody.
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What is the pathophysiology of AHA?
AHA is an autoimmune disease caused by the spontaneous production of neutralizing immunoglobulin G (IgG) autoantibodies (inhibitors) targeting endogenous FVIII. 12, 13 Recent research suggests that the breakdown of immune tolerance is caused by a combination of genetic and environmental factors. 12, 14, 15 What is the risk for bleeding in patients with AHA?
Although 30% of patients do not require hemostatic treatment, bleeding severity varies and can be life threatening and/or limb threatening. 3, 16, 17 In a more recent study, 5 94.6% of patients presented with bleeding: 77% with spontaneous and 70% with serious bleeding (hemoglobin [Hb] < 8 g/dL or a decrease in Hb of >2 g/dL). Because of the second-order kinetics of the anti-FVIII antibodies, FVIII levels are not predictive of bleeding risk and patients can have clinically significant bleeding despite only modestly reduced FVIII activity levels. 2 What is the bleeding pattern in AHA?
Subcutaneous bleeding is most common in AHA (>80%), 3 followed by gastrointestinal bleeding (>20%); muscle bleeding (>40%); and genitourinary, retroperitoneal, and other sites of bleeding (<10%). 2 Intracranial hemorrhage is rare but can be fatal. In contrast to congenital hemophilia A, joint bleeding is infrequent with AHA. 3, 5 What is the risk and cause of death in AHA?
Mortality in AHA is estimated to be 20% among patients >65 years and those with underlying malignancies. 18 Although the primary cause of death is the underlying disease (46%), 5 the cause of death is unknown in many (38%), 17 reflecting limited follow-up in most studies.
Deaths from bleeding are less common: 3.2% of patients (17.2% of all deaths) in EACH2 5 and 9.1% at a median of 19 days after presentation in the UK Haemophilia Centre Doctors' Organisation (UKHCDO) observational study. 3 Although bleeding as a direct cause of death is rare, it is usually a contributor to considerable morbidity that will extend hospitalization, delay healing, and can indirectly result in the death of the patient.
Immunosuppressive therapy (IST) to eliminate the antibodies and decrease bleeding risk is recommended but is associated with mortality, accounting for 16% of all deaths (4.2% of patients) in EACH2. Other fatal and nonfatal complications include thrombotic events such as myocardial infarction and stroke. AHA should be suspected in a nonbleeding patient not on anticoagulation with an isolated prolonged aPTT, a mixing study consistent with an inhibitor, and a negative lupus anticoagulant (LA).
How should AHA be diagnosed?
An isolated prolonged aPTT should always be investigated; an algorithm for diagnosing AHA is provided in Figure 1 A FVIII inhibitor is confirmed and quantified by the Bethesda assay (BA), Nijmegen Bethesda assay (NBA), or in some laboratories by an enzyme-linked immunosorbent assay (ELISA) with anti-FVIII antibody.
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What are the differential diagnoses and potential pitfalls in the laboratory diagnosis of AHA?
Both the BA and NBA may underestimate the inhibitor titer.
Underestimates of the inhibitor titer may be result from nonlinear inactivation of FVIII and residual FVIII activity. Heat treatment of the LA should be excluded as a potential cause of isolated prolonged aPTT.
Studies of aPTT mixing will be abnormal with both AHA and a LA.
While an aPTT mixing study could initially correct the aPTT prolongation, it will again prolong aPTT with incubation because of the time and temperature dependence of anti-FVIII antibodies. LA will usually show an immediate inhibitory effect in the mixing study.
Confounding LA can usually be diagnosed through the use of dilute Russel viper venom time (dRVVT).
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Heparins, heparinoids, and direct anticoagulants may interfere with test results and resemble circulating inhibitors.
Although the effect of these agents on laboratory measurements are highly variable, thrombin clotting time, with or without reptilase time, may be helpful in distinguishing the effects of heparin and direct thrombin inhibitors from AHA. 21 To detect the effects of FXainhibiting anticoagulants (low-molecular-weight heparins, fondaparinux, danaparoid, and direct oral factor Xa inhibitors), an anti-Xa assay is helpful.
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The management of AHA focuses on the following goals:
1. Controlling and preventing bleeding (if present/significant).
2. Eradication of the inhibitor.
Treatment of the underlying disease (if applicable).
Who should manage patients with AHA?
A hematology specialist familiar with the management of patients with coagulation inhibitors, with access to possible hemostatic agents and frequent FVIII monitoring, is best suited to manage patients with AHA.
Available hemostatic agents do not always have predictable efficacy 16 and are administered to patients who often have underlying comorbidities and may have underlying prothrombotic risk factors.
Immunosuppression creates a dynamically changing hemostatic environment that requires close monitoring. For these reasons, patients with AHA are best managed by, or in close consultation with, physicians experienced in AHA.
11,24-26
Which patients with AHA should be treated with hemostatic agents?
Invasive procedures should be avoided-if they are urgently needed, however, hemostatic therapy is required before and after the procedures.
Patients with major bleeding and/or a decrease in hemoglobin require immediate hemostatic treatment.
Patients with mild/moderate bleeding without a significant decrease in hemoglobin may not require immediate hemostatic therapy-but could developing severe bleeding at any time.
Patients at high risk for bleeding (recent surgery, recent delivery, peptic ulcer, etc) require prophylactic hemostatic therapy.
Because severe and potentially life-threatening/limb-threatening bleeding may occur, rapid diagnosis and treatment are critical. Severity of bleeding at presentation does not predict recurrence or subsequent severity of bleeding. 3 Some soft tissue hemorrhage managed without hemostatic therapy can expand into compartment syndrome. Therefore, close monitoring, good patient education, and immediate inhibitor eradication are essential.
11,24,25
How should bleeding be treated in patients with AHA?
Options for first-line hemostatic agents are listed in Table 2 Determination of hemostatic control is largely based on clinical assessment and switch to an alternate hemostatic agent should be considered after 12-24 hours.
Human FVIII (hFVIII) replacement, although effective in patients with low titers (<5 BU), is not effective in patients with high titer inhibitors (>5 BU).
Desmopressin (DDVAP) is of limited utility in AHA.
Antifibrinolytic agents may be a useful adjunct to therapy, particularly for mucosal bleeding, with the exception of renal tract bleeding (risk for urinary outflow obstruction induced by intraureteral or bladder clot formation).
| Replacement therapy
Human FVIII replacement is not effective in the presence of high titer inhibitors. 27 If used in patients with lower titers (<5 BU), the dose must be increased sufficiently to overcome the inhibitor. Especially for patients in geographic locations where other hemostatic alternatives are not readily available, hFVIII replacement could be a sufficient firstline therapy and has proven effective in some patients.
Porcine FVIII (pFVIII) can achieve measurable FVIII levels and hemostasis in AHA, even if the human inhibitor is high. Recombinant porcine FVIII (rpFVIII, Obizur) was approved for the treatment of bleeding in AHA in the United States, Canada, and Europe based on a prospective study in adults with serious bleeding 28 : all 28 subjects had good hemostasis and FVIII activity levels >100% within 24 hours in response to rpFVIII. The FVIII activity on response to rpFVIII was dependent on a cross-reactive pFVIII inhibitor titer. Subjects without cross-reactivity (pFVIII inhibitor negative) achieved very high FVIII activity levels (118%-522%).
To predict the effectiveness of either hFVIII or rpFVIII in the treatment of AHA, it is essential to determine baseline concentrations of anti-human and anti-porcine FVIII antibodies (performed in specialty laboratories). Administration of rpFVIII will trigger an increase in the anti-rpFVIII titer in some patients, 28 and can subsequently decrease treatment efficacy. Baseline and postinfusion FVIII levels should be used to guide dosing and intervals.
| Bypassing agents
Recombinant factor VIIa (rFVIIa, NovoSeven Table 2 .
In EACH2-prior to approval of rpFVIII-most patients treated with hemostatic agents received rFVIIa (56.7%); others received aPCC (20.5%), hFVIII (18.2%), or DDAVP (4.6%). 16 Overall, bleeding was controlled most successfully with bypassing agent (91.8%), with no difference between rFVIIa (91.8%) and aPCC (93.3%). Replacement with hFVIII concentrate was less successful in controlling bleeding (69.6%).
| Other hemostatic approaches
The use of DDVAP for the management of bleeding should be reserved for minor bleeding in patients with low inhibitor titers (<2 BU/mL) and FVIII levels >5 IU/. 16, 20, 24, 29 The ability of DDVAP to release FVIII from endothelial cells is unpredictable and DDVAP is associated with a substantial risk for adverse events in elderly patients.
Tranexamic acid (TA) in combination with either aPCC or rFVIIa normalizes clot stability, 30, 31 and case reports on combination of TA 
Comments
Patients should also be started on IST and FVIII level monitors regularly. Head to head comparison of these hemostatic agents have not been done and the first line agent should be chosen based on availability, prior efficacy in the patient and economic considerations. Hemostatic efficacy is largely based on clinical assessment and changing to an alternate hemostatic agent should be considered after 12-24 h. Once hemostasis is achieved, the dosing frequency of any hemostatic agent should be decreased as tolerated to prevent the risk for thrombosis. Hemostatic agents should not be given in a patient with rising factor levels and no active or increased risk for bleeding. In hospitalized patients consider thromboembolism prophylaxis when FVIII levels exceed 50 IU/dL. AHA: acquired hemophilia A; FVIII: factor VIII; IST: immunosuppressive therapy; rpFVIII: recombinant porcine factor VIII. a rpFVIII dosing recommendations differ from package inset and are based on the postmarketing clinical experience with this medication. What is the definition of response to hemostatic therapy?
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Response to therapy is determined clinically.
Response to human and porcine FVIII replacement can be monitored with FVIII activity assays.
There is no established laboratory monitoring assay for bypassing agents.
Monitoring response relies on clinical assessment, hemoglobin, and imaging studies. No laboratory tests have been standardized for monitoring hemostatic response to bypassing agents. [36] [37] [38] Routine FVIII levels using 1-stage coagulation assays can be used to measure human or porcine FVIII concentrates. 39 FVIII levels should be obtained in real time (turnaround of 1-2 hours) to be clinically useful and guide subsequent management, which is not possible at many institutions. The more readily available aPTT will normalize when replacement results in FVIII levels >30%-50% (laboratory dependent), but it is not a predictor of supra-therapeutic levels.
Thus, aPTT level is not a good surrogate marker to guide treatment.
Are there factors that predict response to hemostatic therapy?
Neither residual FVIII activity levels nor inhibitor titers correlate with the severity or responsiveness of bleeds.
3
What are the risks associated with the use of bypassing agents?
Patients receive bypassing agents are at risk for arterial and venous thromboembolism, and should be monitored closely.
Particular caution is recommended in older patients and patients
with predisposing conditions (eg, underlying malignancy or personal history of thrombosis).
The risk for thromboembolic complications, including disseminated intravascular coagulation, among patients who are treated with bypassing agents is increased (Table 3) . 6, 8, 16, [40] [41] [42] Thrombotic events appear to be associated with age and underlying conditions, such as previous thrombosis, immobilization, malignancy, indwelling catheters, artificial heart valves, vascular grafts, atrial fibrillation, and pregnancy/postpartum. 16 The economic impact of hemostatic management 
| INHIBITOR ERADICATION Who should receive IST to facilitate inhibitor eradication?
IST is recommended in all adult patients with AHA.
Although in some cases inhibitors can disappear spontaneously after several months, 1 while they are present, bleeding-related morbidity and mortality are substantial and hemostatic treatment is costly. Thus,
IST is recommended for all adults with AHA. The role for pediatric patients is not well established because of a lack of data.
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What is the optimal strategy for inhibitor eradication?
Options for first-line IST are summarized in Table 4 IST achieves remission in about 60%-80% of patients after a median of 5-6 weeks. Some evidence suggests that time to remission may be shorter in patients receiving a combination of corticosteroids and cyclophosphamide, although long-term survival does not differ.
The recommendations made here are largely derived from observations made in the UKHCDO surveillance study, 3 the EACH2 registry, 17 and the GTH-AH registry. 8 Both the UKHCDO study and EACH2 collected reallife, nonrandomized data comparing the efficacy of different treatments.
The GTH-AH study prospectively investigated a standardized treatment.
The UKHCDO study showed no statistically different median time to remission between corticosteroids alone (usually prednisolone 1 mg/kg daily, n 5 40; 49 days; 95% CI, 31-62) and corticosteroids/ cytotoxic agents (same dose steroids and usually cyclophosphamide 1-2 mg/kg daily, n 5 48; 39 days; 95% CI, 35-47). A meta-analysis of 20 studies enrolling a total of 249 patients also concluded that cyclophosphamide, with or without corticosteroids (n 5 99), was more effective in achieving complete remissions than corticosteroids alone (n 5 57) or no IST (n 5 27).
2
The GTH-AH study, representing the most robust prospective registry, used a predefined consensus protocol. 8 All patients (n 5 102)
were enrolled within 7 days of starting IST and initially received corti- 
Who is a candidate for second-line and later-line therapy?
Patients who fail to see a decline in the inhibitor titer or a rise in the baseline FVIII level after 3-5 weeks of first-line therapy should be considered for second-line therapy.
Insufficient data are available to recommend specific second-line and 46 immune tolerance protocols, [48] [49] [50] or the combination MBMP.
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What is the role of intravenous immunoglobin (IVIG)?
IVIG has a limited role in the treatment of AHA.
In the EACH2 study, adding IVIG to other immunosuppressive agents as first-line therapy provided no benefit. 17 A similar result was seen in the UKHCDO surveillance study 3 and in a subsequent literature review. 2 IVIG is part of the MBMP 35 and may serve a purpose in the context of this combination therapy. 
Comments
Median time to response (FVIII activity level restored to >50 IU/dL) is 5 wk. Patients with FVIII activity level < 1 IU/dL at baseline require significantly longer times to remission compared to patients with FVIII activity level 1 IU/dL and may require combination IST rather than corticosteroids alone. FVIII activity and inhibitor levels should be monitored at least weekly. Apply individualized therapy according to the patient's general condition, underlying and concomitant diseases, and prognostic factors (ie, FVIII < 1 IU/dL, inhibitor titer > 20 BU/mL, presence of anti-FVIII-IgA antibodies, etc), when available.
AHA: acquired hemophilia A; CR: complete remission; IST: immunosuppressive therapy; IV: intravenous; PO: orally; WBC: white blood cell. a Few data available in AHA, but reports available in other autoimmune disorders.
Are there any clinical characteristics that predict response to first-line immunosuppression?
FVIII < 1 IU/dL and poor performance status are associated with lower remission and survival rates.
Underlying etiology, age, or, sex do not influence time to remission, 8, 17 but a multivariate analysis in the GTH-AH study indicated that FVIII concentration < 1 IU/dL and poor performance status were independently associated with lower CR rate and overall survival. 8 Patients with a FVIII 1 IU/dL and inhibitor titer < 20 BU/mL had a 53% chance of achieving a FVIII > 50 IU/dL by 21 days with corticosteroids alone, compared with a 9% with a FVIII < 1 IU/dL or an inhibitor titer 20 BU/mL.
What is the risk of relapse after initial remission?
After achieving remission, patients should be closely monitored for relapse.
Patients with anti-FVIII autoantibodies of the immunoglobulin A (IgA)
class appear to have a particularly high risk of relapse.
In EACH2, relapse occurred in 18% of patients who achieved remission with corticosteroids alone, and in 12% receiving corticosteroids/cyclophosphamide, with similar time to relapse (134 and 139 days, respectively). Patients achieving remission after rituximab-based regimens had a lower relapse rate of 3%. After a median observation time of 262 days, the proportion of patients who were alive and inhibitor free was similar (steroids only, 67%; steroids and cyclophosphamide, 62%; or rituximab-based regimens, 71%). 17 In the GTH-AH study, the median observation time was 403 days, with 48% of patients alive and in stable CR at database closure. 8 In a post hoc analysis of the GTH-AH study, anti-FVIII autoantibodies of the IgA isotype, detected in 46% of patients, were a potential marker for early relapse. 51 No evidence is available to recommend specific treatment regimens for patients who relapse. In the GTH-AH study, the last effective dose of corticosteroids was recommended if FVIII activity decreased to <50 IU/dL and achieved remission in 18 of 19 patients. 8 What are the complications of IST?
Complications of IST are frequent and can be fatal.
Patients should be monitored closely for signs of infection and other adverse effects of IST.
IST increases infectious risk in this elderly, fragile population. In the UK surveillance study, sepsis was reported in 33% and contributed to death in 12%. 3 In the GTH-AH study, 54 infections were recorded in 37 of 102 patients. 8 Infections occurred after a median of 54 days (IQR 33-137) of starting IST, and 16 of 102 patients died from infection. A similar rate of death from IST (12%) was reported in the SACHA (Surveillance des Auto antiCorps au cours de l'H emophilie Acquise) registry. 6 In the EACH2 registry 4.2% died from complications of IST. Prophylactic antibiotic therapy has not been studied in AHA.
Other well-recognized complications of steroid therapy include raised blood sugar levels (12%), gastrointestinal ulcers (4%), muscle disorders (4%), and psychiatric disorders (3%).
3,8
How should patients be monitored?
Inhibitor titer and FVIII activity should be monitored at least weekly during immunosuppressive treatment.
In the absence of data to support a specific monitoring and tapering schedule, the consensus of the expert panel was to monitor with FVIII activity levels and inhibitor titers weekly until the inhibitor becomes undetectable and FVIII activity levels normalize. Tapering of IST should be initiated once the inhibitor is undetectable and FVIII is rising. FVIII activity should be monitored for some period after IST is stopped to assess for recurrence.
It is important to educate patients on the urgent and immediate need to return to the clinic in case of bleeding symptoms, which could be a sign of inhibitor recurrence.
When is thromboprophylaxis appropriate?
Nonbleeding hospitalized patients with FVIII activity levels > 50 IU/dL should receive thromboprophylaxis.
If a patient has a prior indication for aspirin or anticoagulation, it should be restarted when the FVIII activity consistently exceeds 50 IU/dL.
Data are limited on thrombotic risk in patients receiving hemostatic agents and responding to IST (Table 3) prior need for full anticoagulation should restart such at this point.
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Pregnancy-associated AHA may resolve spontaneously.
IST with corticosteroids alone should be considered as first-line therapy to avoid potential bleeding complications in the mother and baby.
Cyclophosphamide is not safe during pregnancy/lactation.
Pregnancy-associated AHA typically occurs with the first pregnancy. It is usually diagnosed several days to months postpartum but can present peripartum, [1] [2] [3] [4] [5] [6] [7] 10, 52 and the transplacental crossing of the IgG antibodies poses a potential hemorrhagic risk for the neonate. 11 Bleeding patterns are of similar severity and distribution as other AHA, with the addition of significant uterine/vaginal bleeding. 52 Hemostatic management is achieved as with other patients with AHA, although no data are available on the use of rpFVIII during pregnancy. Overall survival is superior to patients with AHA associated with other etiologies. 52 AHA associated with pregnancy (rather than other etiologies) may require a longer time to remit fully, although the rate of spontaneous remission may be higher. [53] [54] [55] Relapse during subsequent pregnancies appears uncommon. 55, 56 Steroids are a safe and effective way to eradicate inhibitors around pregnancy. 52 Few data are available on the efficacy and safety of IST for pregnancy-associated AHA. A single-center case series suggests that rituximab is effective in this setting. 57 
| C O NC LU S I O N S
AHA is a rare disorder with high potential for morbidity and mortality.
Because it occurs in patients without a known bleeding disorder, the internist or emergency department provider is often the first to evaluate the patient. For most patients, AHA is eminently treatable, with clear benefits from prompt recognition and appropriate management.
Both hemostatic and immune therapy impose considerable risks and require close monitoring to ensure safety.
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